专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007032028A8 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS 审中-公开
标题翻译：噻吗啉和氧化氮及其作为PTP1B抑制剂的用途
公开(公告)号：WO2007032028A8
公开(公告)日：2008-07-17
申请号：PCT/IN2006000368
申请日：2006-09-15
申请人： TORRENT PHARMACEUTICALS LTD , BANERJEE RAKESH KUMAR , GUPTA RAMESH CHANDRA , TULI DAVINDER , RODE MILIND , SUTHAR BHARAT , UMRANI DHANANJAY , PATHAK PADMAJA , CHOKSI TEJAL , CHAUDHARY ANITA
发明人： BANERJEE RAKESH KUMAR , GUPTA RAMESH CHANDRA , TULI DAVINDER , RODE MILIND , SUTHAR BHARAT , UMRANI DHANANJAY , PATHAK PADMAJA , CHOKSI TEJAL , CHAUDHARY ANITA
IPC分类号： C07D277/42 , A61K31/42 , A61K31/425 , A61P3/10 , C07D263/48 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07F9/6539
CPC分类号： C07F9/6539 , C07D263/48 , C07D277/20 , C07D277/42 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The present invention encompasses; the novel substituted heterocyclic compounds represented by formula (I) or their pharmaceutically acceptable salts, wherein the substituents in formula (I) have the meanings as defined in the specification. The invention also encompasses process for preparing such compound, pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases.
摘要翻译：本发明包括由式（I）表示的新型取代的杂环化合物或其药学上可接受的盐，其中式（I）中的取代基具有如说明书中所定义的含义。本发明还包括制备这种化合物的方法，药物组合物和治疗或预防PTP-1B介导的疾病的方法。

2. 发明申请

WO2008149379A3 NOVEL COMPOUNDS 审中-公开
标题翻译：新型化合物
公开(公告)号：WO2008149379A3
公开(公告)日：2009-03-19
申请号：PCT/IN2008000345
申请日：2008-06-02
申请人： TORRENT PHARMACEUTICALS LTD , CHHIPA LAXMIKANT , ZAMBAD SHITALKUMAR PUKHARAJ , GUPTA RAMESH , TULI DAVINDER , KASUNDRA ASHOK , MUNSHI SIRALEE , SIDDIQUI M AMIR , BHATTAMISRA SUBRAT KUMAR , DUTT C , CHAUTHAIWALE VIJAY
发明人： CHHIPA LAXMIKANT , ZAMBAD SHITALKUMAR PUKHARAJ , GUPTA RAMESH , TULI DAVINDER , KASUNDRA ASHOK , MUNSHI SIRALEE , SIDDIQUI M AMIR , BHATTAMISRA SUBRAT KUMAR , DUTT C , CHAUTHAIWALE VIJAY
IPC分类号： C07D231/14 , A61K31/4155 , A61P3/04 , C07D403/06 , C07D409/04
CPC分类号： C07D403/06 , C07D231/12 , C07D231/14 , C07D231/18 , C07D403/10 , C07D403/12 , C07D409/04 , C07D413/06
摘要： The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3 R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.
摘要翻译：本发明公开了一种新颖的甲状腺类似式（I）化合物，其中R1 R2，R3R4和Z如本说明书中所定义，其制备方法，含有这些化合物的组合物以及这些化合物的使用以及组合物作为药物。此外，式（I）化合物对甲状腺受体具有显着低的结合亲和力，因此显着缺乏甲状腺毒性作用。本发明还涉及式（I）化合物在制备用于治疗各种疾病状况如肥胖，血脂异常，代谢综合征和与代谢综合征相关的并发症的药物中的用途。

3. 发明专利

EA019084B1 НОВЫЕ ТИРЕОИДНЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С НАРУШЕНИЕМ ОБМЕНА ВЕЩЕСТВ 未知
公开(公告)号：EA019084B1
公开(公告)日：2014-01-30
申请号：EA200901651
申请日：2008-06-02
申请人： TORRENT PHARMACEUTICALS LTD
发明人： CHHIPA LAXMIKANT , ZAMBAD SHITALKUMAR PUKHARAJ , GUPTA RAMESH , TULI DAVINDER , KASUNDRA ASHOK , MUNSHI SIRALEE , SIDDIQUI M AMIR , BHATTAMISRA SUBRAT KUMAR , DUTT C , CHAUTHAIWALE VIJAY
IPC分类号： C07D231/14 , A61K31/4155 , A61P3/04 , C07D403/06 , C07D409/04
摘要： Визобретенииописаныновыетиреоидныесоединенияформулы (I)где R, R, R, Rи Z определеныв описании, способполучения, композиция, содержащаятакиесоединения, иприменениетакихсоединенийи композициив качествелекарственногопрепарата. Крометого, соединенияформулы (I) имеютсущественноболеенизкоесродствок связываниюс рецепторамищитовиднойжелезыи, следовательно, взначительнойстепенилишенытиреотоксическихэффектов. Изобретениетакжеотноситсяк применениюсоединенияпоформуле (I) дляполучениялекарственногопрепаратадлялеченияразличныхзаболеваний, такихкакожирение, дислипидемия, метаболическийсиндроми сопутствующиепатологии, связанныес метаболическимсиндромом.

4. 发明专利

HK1129221A1 NOVEL COMPOUNDS 未知
公开(公告)号：HK1129221A1
公开(公告)日：2009-11-20
申请号：HK09106665
申请日：2009-07-21
申请人： TORRENT PHARMACEUTICALS LTD
发明人： CHHIPA LAXMIKANT , ZAMBAD SHITALKUMAR PUKHARAJ , GUPTA RAMESH , TULI DAVINDER , KASUNDRA ASHOK , MUNSHI SIRALEE , SIDDIQUI M AMIR , BHATTAMISRA SUBRAT KUMAR , DUTT C , CHAUTHAIWALE VIJAY
IPC分类号： A61K20060101 , A61P20060101 , C07D20060101
摘要： The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

5. 发明专利

CA2698704C NOVEL COMPOUNDS 未知
公开(公告)号：CA2698704C
公开(公告)日：2016-01-19
申请号：CA2698704
申请日：2008-06-02
申请人： TORRENT PHARMACEUTICALS LTD
发明人： CHHIPA LAXMIKANT , ZAMBAD SHITALKUMAR PUKHARAJ , GUPTA RAMESH , TULI DAVINDER , KASUNDRA ASHOK , MUNSHI SIRALEE , SIDDIQUI M AMIR , BHATTAMISRA SUBRAT KUMAR , DUTT C , CHAUTHAIWALE VIJAY
IPC分类号： C07D231/14 , A61K31/4155 , A61P3/04 , C07D403/06 , C07D409/04
摘要： The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3' R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

6. 发明专利

CA2852615A1 NOVEL SUBSTITUTED IMIDAZOPYRIMIDINES AS GPBAR1 RECEPTOR MODULATORS 未知
公开(公告)号：CA2852615A1
公开(公告)日：2013-04-25
申请号：CA2852615
申请日：2012-10-15
申请人： TORRENT PHARMACEUTICALS LTD
发明人： DUTT CHAITANYA , CHAUTHAIWALE VIJAY , GUPTA RAMESH CHANDRA , GHALSASI SAMEER , TULI DAVINDER , DESHPANDE SHAILESH , CHAUDHARI ANITA , ZAMBAD SHITALKUMAR
IPC分类号： C07D487/04 , A61K31/519 , A61P3/00 , A61P9/00
摘要： The present invention relates to novel substituted imidazo[1,2-a]pyrimidine compounds of formula (I), their pharmaceutically acceptable salts, and their isomers, stereoisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further" relates to the use of the above- mentioned compounds for the preparation of medicament for use as pharmaceuticals. (Formula I).

7. 发明专利

ES2351274T3 NUEVOS COMPUESTOS. 未知
公开(公告)号：ES2351274T3
公开(公告)日：2011-02-02
申请号：ES08772567
申请日：2008-06-02
申请人： TORRENT PHARMACEUTICALS LTD
发明人： CHHIPA LAXMIKANT , TULI DAVINDER , BHATTAMISRA SUBRAT KUMAR , ZAMBAD SHITALKUMAR PUKHARAJ , GUPTA RAMESH , DUTT C , SIDDIQUI M AMIR , MUNSHI SIRALEE , CHAUTHAIWALE VIJAY , KASUNDRA ASHOK
IPC分类号： C07D231/14 , A61K31/4155 , A61P3/04 , C07D403/06
摘要： Un compuesto de fórmula (I) **(Ver fórmula)** en la que R1 y R3 son iguales o diferentes, y se seleccionan independientemente de H, alquilo (C1-C6), cicloalquilo (C3-C7), halo, CN, CF3, -O-alquilo (C1-C6), -CO2-alquilo (C1-C6), COOH, -CONH-alquilo (C1-C6), -CONH-arilo, -NH2, -CONH-R6, -CONR5, -alquil C1-C3-arilo, -alquil (C1-C3)-R6, -NH-alquilo (C1-C6), -NHarilo, -NH-SO2-alquilo (C1-C6), -CH2-NH-alquilo (C1-C6), -CH2-O-alquilo (C1-C6), -alquil C1-C3-NR5R6R7, en los que alquilo C1-C6 y cicloalquilo C3-C7 están opcionalmente sustituidos con uno o más sustituyentes seleccionados de alquilo (C1-C6), halo, ciano, -OH, oxo, -COOH, -O-alquilo (C1-C6), -O-bencilo, -COO-alquilo (C1-C6), -CONH-alquilo (C1-C6), -CONR5, -CONH-arilo, -CONH-heteroarilo o -CH2NR5; R2 se selecciona de alquilo (C1-C6), cicloalquilo (C3-C6), alquenilo (C3-C6), alquinilo (C3-C6), -C(O)-alquil (C1-C3)-COOH, -alquil (C1-C3)-COOH, -C(O)-alquil (C1-C3)-COO-alquilo, -C(O)-C(O)O-alquilo (C1-C6), -C(O)-alquil (C1-C3)-NH-alquilo (C1-C6), -C(O)-O-alquilo (C1-C6), -C(O)NR5, -C(O)NH-alquilo (C1-C6), -C(O)-alquil (C1-C3)arilo, -C(O)-alquilo (C1-C3)-R6, R6, R7, en el que dichos alquilo (C1-C6), cicloalquilo (C3-C6), alquenilo (C3-C6), alquinilo (C3-C6) están opcionalmente sustituidos con uno o más sustituyentes seleccionados de perhaloalquilo, oxo, -C(O)OH, -C(O)-O-alquilo (C1-C3), -C(O)-O-alquil (C1-C3)-arilo, -C(O)-O-alquil (C1-C3)-R6, -CONH2, -CONH-alquilo (C1-C3), -C(O)NH-arilo, -C(O)NH-R6, -CONR5-CONHNH2, -C(=NH)NH-alquilo (C1-C6), -C(=NH)NH2, C(=NH)NHOH, -C(O)-R8, -C(O)NHSO2-alquilo (C1-C6), -C(O)NHSO2-arilo, -C(O)NHOH, -C(O)NHSO2-R6, -C(O)NHNH-alquilo (C1-C6), -C(O)NHNH-arilo, -CONH-alquil (C1-C2)-arilo, -C(O)NH-alquil (C1-C2)-R6, -CH2NR5, -NH2, -NH-alquilo (C1-C6), -NH-C(O)-O-alquilo (C1-C3), -NH-C(O)-alquilo (C1-C3), -NHC(O)-arilo, -NHC(O)-alquil (C1-C3)arilo, -NHC(O)-R6, -NH-C(O)NR5, -NH-C(O)NH-arilo, -NHC(O)NH-alquilo (C1-C6), -NHSO2-alquilo (C1-C6), -NH-SO2-arilo, -NH-SO2-R6, halo, ciano, -OH, -O-alquilo (C1-C6), -O-arilo, -O-heteroarilo, -O-alquil (C1-C2)-arilo, -SO3H, -SO2NH-arilo, -SO2NH-R6 o -SO2NH-alquilo (C1-C6), R6 o R7; R5, junto con el átomo de nitrógeno al que está unido, forma un anillo de (C3-C6) miembros, saturado o insaturado, que puede contener además 1-2 heteroátomos seleccionados de O, N o S y que puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados de oxo, -COOH, halo, -OH, -O-alquilo (C1-C6), o -alquilo (C1-C6); R6 se selecciona de fenilo o heteroarilo de 5-8 miembros que tiene 1-4 heteroátomos seleccionados de O, N o S, en el que dicho anillo heteroarilo o fenilo está opcionalmente sustituido con uno o más sustituyentes seleccionados de halógeno, -OH, -O-alquilo (C1-C6), -perhaloalquilo, -alquilo (C1-C6), -cicloalquilo (C3-C6), -SO2-alquilo (C1-C6), ciano, -COOH, -C(O)O-alquilo (C1-C6), -C(O)O-CH2-arilo, -C(O)O-arilo, -CONH-alquilo (C1-C3), nitro, -NH2, -NH-alquilo (C1-C6), -NHC(O)-alquilo (C1-C6), -NHC(O)-arilo, -NHSO2-alquilo (C1-C6), -CONH2, -SO2-alquilo (C1-C6), -NHSO2-alquilo (C1-C6) o -COR8; R7 es un anillo heterocíclico de 3-6 miembros que contiene 1-4 heteroátomos seleccionados de O, N o S, y el mencionado anillo heterocíclico está opcionalmente sustituido con uno o más sustituyentes seleccionados de oxo, halógeno, -O-alquilo (C1-C6), -OH, -CF3, alquilo (C1-C6), cicloalquilo (C3-C6), ciano, -COOH, -C(O)O-alquilo (C1-C6), -C(O)O-CH2-arilo, -C(O)O-arilo, -NH2, -NH-alquilo (C1-C6), -NHC(O)-alquilo (C1-C6), -NHC(O)-arilo, -CONH2, -SO2aril-alquilo (C1-C6), -SO2-alquilo (C1-C6), -NHSO2-alquilo (C1-C6) o -COR8; R8 es un aminoácido que está enlazado a través de su átomo de nitrógeno; Z = O, CH2 o NH; R4 se selecciona de P, Q o T **(Ver fórmula)** R9 se selecciona de -OH, -O-alquilo, -OSO3H, halógeno, -C(O)O-alquilo (C1-C6), -C(O)NHR8, -OC(O)-alquilo (C1-C6), -O-perhaloalquilo, -OC(O)O-alquilo (C1-C6), -CONR5-NHCO-alquilo (C1-C6), -NHC(O)-O-alquilo (C1-C6), -NHC(O)-O-arilo, -NHSO2-alquilo (C1-C6), -NHSO2-arilo, -NHCONR5 o; **(Ver fórmula)** R10 se selecciona de H, halógeno, alquilo (C1-C6), alcoxi, ariloxi, -NHCO-alquilo (C1-C6), -NHSO2-alquilo (C1-C6) o -NH-SO2-arilo; R11 es -CO-alquilo (C1-C6), -SO2-alquilo (C1-C6) o -SO2-arilo; G' se selecciona de H, halógeno o alquilo (C1-C6); G'' se selecciona de hidrógeno, alquilo (C1-C6), cicloalquilo (C3-C6), arilo, halógeno, perhaloalquilo, CN, CHO, -alquil (C1-C3)arilo, -alquil (C1-C6)-O-alquilo (C1-C6), -CH2R9, -CH2arilo, -CH2NR5, -COOH, -C(O)O-alquilo (C1-C6), -CONH-alquilo (C1-C6), -CONR5, -SO2NR5, -SO2NH-alquilo (C1-C6), -SO2NH-arilo; n puede ser uno o dos; con la condición de que: cuando R4 es Q, entonces R2 es diferente de R6 y R7; incluyendo sus sales farmacéuticamente aceptables y sus hidratos, solvatos, atropisómeros, regioisómeros, enantiómeros, diastereómeros, tautómeros, y polimorfos del mismo.

8. 发明专利

HRP20100611T1 NOVEL COMPOUNDS 未知
公开(公告)号：HRP20100611T1
公开(公告)日：2010-12-31
申请号：HRP20100611
申请日：2010-11-11
申请人： TORRENT PHARMACEUTICALS LTD
发明人： CHHIPA LAXMIKANT , ZAMBAD SHITALKUMAR PUKHARAJ , GUPTA RAMESH , TULI DAVINDER , KASUNDRA ASHOK , MUNSHI SIRALEE , SIDDIQUI M AMIR , BHATTAMISRA SUBRAT KUMAR , DUTT C , CHAUTHAIWALE VIJAY
IPC分类号： C07D231/14 , A61K31/4155 , A61P3/04 , C07D403/06
摘要： The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

9. 发明专利

AU2006290250A1 Thiazolinones and oxazolinones and their use as PTP1B inhibitors 未知
公开(公告)号：AU2006290250A1
公开(公告)日：2007-03-22
申请号：AU2006290250
申请日：2006-09-15
申请人： TORRENT PHARMACEUTICALS LTD
发明人： GUPTA RAMESH CHANDRA , TULI DAVINDER , CHAUDHARY ANITA , UMRANI DHANANJAY , RODE MILIND , SHUTHAR BHARAT , CHOKSI TEJAL , PATHAK PADMAJA , BANERJEE RAKESH KUMAR
IPC分类号： C07D277/42 , A61K31/42 , A61K31/425 , A61P3/10 , C07D263/48 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07F9/6539
摘要： The present invention encompasses; the novel substituted heterocyclic compounds represented by formula (I) or their pharmaceutically acceptable salts, wherein the substituents in formula (I) have the meanings as defined in the specification. The invention also encompasses process for preparing such compound, pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases.

10. 发明专利

AR108327A1 COMPUESTOS PIRIMIDINONA FUSIONADOS SUSTITUIDOS 未知
公开(公告)号：AR108327A1
公开(公告)日：2018-08-08
申请号：ARP170101057
申请日：2017-04-26
申请人： TORRENT PHARMACEUTICALS LTD
发明人： ABRAHAM JAYA , MISHRA VIVEK , DESHPANDE SHAILESH , JAMADARKHANA PRASHANT , RAI DEEPAK , GUPTA RAMESH CHANDRA , TULI DAVINDER , SRIVASTAVA SANJAY , RODE MILIND , JOSHI DEEPA , DUTT CHAITANYA
IPC分类号： C07D487/04 , A61K31/4162 , A61K31/519 , A61P11/00 , A61P11/06 , A61P37/00
摘要： Reivindicación 1: Un compuesto de la fórmula (1) donde, X es una unión o un resto de fórmula (2); * denota el punto de acople al anillo A y al resto de la molécula; cuando X es una unión, el anillo A es un heteroarilo mono o bicíclico conteniendo por lo menos un N y ese N es el punto de acople a X; o cuando X es el resto de fórmula (2), el anillo A es arilo o heteroarilo mono o bicíclico; el anillo B es arilo mono o bicíclico o un heteroarilo de 6 miembros; R¹ y R² se seleccionan independientemente de hidrógeno, halógeno, NO₂, NR¹¹R¹², CF₃, CN, COOR⁹, COR⁹, OR⁹, OCOR⁹, O-C₁₋₆ alquil-OR⁹, O-C₁₋₆ alquil-S(O)ₜR⁹, O-C₁₋₆ alquil-NR¹¹R¹², O-C₁₋₆ alquil-COOR⁹, O-C₁₋₆ alquil-COR⁹, S(O)ₜR⁹, C₁₋₆ alquil, C₃₋₆ cicloalquilo, C₁₋₆ alquil-OR⁹, C₁₋₆ alquil-S(O)ₜR⁹, C₁₋₆ alquil-NR¹¹R¹², C₁₋₆ alquilarilo, C₁₋₆ alquilheteroarilo, C₁₋₆ alquilheterocicloalquilo, C₁₋₆ alquilcicloalquilo, C₂₋₅ alquenil-R¹³, C₂₋₅ alquinil-R¹³, heterocicloalquilo, arilo, éster boronato y heteroarilo; dicho C₃₋₆ cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente sustituidos por R¹⁰; R³ y R⁴ se seleccionan independientemente de hidrógeno, OR⁹, halógeno, NR¹¹R¹², NO₂, CF₃, O-C₁₋₆ alquil-OR⁹, O-C₁₋₆ alquil-S(O)ₜR⁹, O-C₁₋₆ alquil-NR¹¹R¹², O-C₁₋₆ alquil-COOR⁹, O-C₁₋₆ alquil-COR⁹, S(O)ₜR⁹, COR⁹, COOR⁹, C₁₋₆ alquil, C₃₋₆ cicloalquilo, C₂₋₅ alquenil-R¹³, C₂₋₅ alquinil-R¹³ arilo, heteroarilo y heterocicloalquilo; ese C₃₋₆ cicloalquilo, heterocicloalquilo, arilo y heteroarilo está opcionalmente sustituido por R¹⁰; R⁵, R⁶, R⁷ y R⁸ se seleccionan independientemente de hidrógeno, halógeno, NR¹¹R¹², CF₃, COOR⁹, COR⁹, y C₁₋₆ alquilo, o R⁵ y R⁶ o R⁷ y R⁸ juntos podrán formar un anillo cicloalquilo monocíclico de 3 a 6 miembros; R⁹ se selecciona independientemente de hidrógeno, NR¹¹R¹², CF₃, SO₃H, glucuronato, C₁₋₆ alquilo, C₁₋₆ alquil-R¹⁰, C₃₋₆ cicloalquilo, heterocicloalquilo, arilo y heteroarilo; ese C₃₋₆ cicloalquilo, heterocicloalquilo, arilo y heteroarilo está opcionalmente sustituido por R¹⁰; R¹⁰ se selecciona independientemente de hidrógeno, oxo, halógeno, CF₃, S(O)ₜR⁹, OR⁹, NO₂, COR⁹, COOR⁹, NR¹¹R¹², N(R⁹)COR⁹, N(R⁹)S(O)ₘR⁹,y OCOR⁹, C₁₋₆ alquilo, C₃₋₆ cicloalquilo, C₁₋₆ alquil-OR⁹, C₁₋₆ alquil-COOR⁹, C₁₋₆ alquil-COR⁹, C₁₋₆ alquil-S(O)ₜR⁹, C₁₋₆ alquil-NHCOR⁹, C₁₋₆ alquil-NHS(O)ₜR⁹, C₁₋₆ alquil-NR¹¹R¹², heterocicloalquilo, arilo, heteroarilo, C₂₋₅ alquenil-R¹³ y C₂₋₅ alquinil-R¹³; R¹¹ y R¹² se seleccionan independientemente de hidrógeno, COR⁹, N(R⁹)₂, N(R⁹)S(O)ₜR⁹, N(R⁹)COR⁹, CF₃, S(O)ₜR⁹, C₁₋₆ alquilo, fluoro-C₁₋₆ alquilo, arilo, heteroarilo, heterocicloalquilo, C₃₋₆ cicloalquilo, C₁₋₆ alquil-C₃₋₆ cicloalquilo, C₁₋₆ alquilheterocicloalquilo, C₁₋₆ alquilarilo, C₁₋₆ alquilheteroarilo, C₁₋₆ alquil-OR⁹, C₁₋₆ alquil-S(O)ₜR⁹, C₁₋₆ alquil-COOR⁹, C₁₋₆ alquil-COR⁹, C₁₋₆ alquil-OCOOR⁹, C₁₋₆ alquil-N(R⁹)COR⁹ y C₁₋₆ alquil-N(R⁹)S(O)ₘR⁹; o R¹¹ y R¹² junto con N, podrán formar un anillo heterociclo de 3 a 8 miembros monocíclico o de 8 a 12 miembros bicíclico, donde ese anillo mono y bicíclico podrá contener adicionalmente 1, 2 y 3 heteroátomos en el anillo seleccionados de O, S(O)ₜ o N; ese heterociclo está opcionalmente sustituido por R¹⁰; R¹³ se selecciona independientemente de hidrógeno, C₁₋₆ alquil-OR⁹, C₁₋₆ alquil-S(O)ₜR⁹, C₁₋₆ alquil-COOR⁹, C₁₋₆ alquil-COR⁹, C₁₋₆ alquil-OCOOR⁹, C₁₋₆ alquil-N(R⁹)COR⁹, C₁₋₆ alquil-N(R⁹)S(O)ₘR⁹, C₁₋₆ alquil-NR¹¹R¹², arilo, heteroarilo, C₃₋₆ cicloalquilo, heterocicloalquilo, C₁₋₆ alquil-C₃₋₆ cicloalquilo, C₁₋₆ alquilheterocicloalquilo, C₁₋₆ alquilheteroarilo y C₁₋₆ alquilarilo; ese C₁₋₆ alquil-C₃₋₆ cicloalquilo, C₁₋₆ alquilheterocicloalquilo, C₁₋₆ alquilheteroarilo, C₁₋₆ alquilarilo, C₃₋₆ cicloalquilo, heterocicloalquilo, arilo y heteroarilo está opcionalmente sustituido por R¹⁰; Z es CH₂ ó O; q es 1 - 3; n se selecciona de 1 - 4; p y m son independientemente 1 ó 2; y t se selecciona de 0 - 2; o sales, metabolitos, isómeros, estereoisómeros, atropisómeros, confórmeros, tautómeros, polimorfos, hidratos o solvatos farmacéuticamente aceptables de los mismos.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式